They accused him of having produced a fraudulent report in November 2018 for Genevrier Laboratories in exchange for a large payment (more than €250,000) in defence of a delisted drug, Chondrosulf.
They alleged that he had fabricated a false report in November 2018 on behalf of Genevrier Laboratories in exchange for a substantial payment (over €250,000) to defend the delisted medication Chondrosulf.